{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:47:07Z","timestamp":1792900027092,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) induce T-cell-mediated antitumour responses. While ICI were initially successfully applied in metastasized melanoma, they are now approved for several tumour entities. Numerous autoimmune disorders have been reported to occur as adverse events of the treatment, among them bullous pemphigoid (BP), with less than 1% of the patients experiencing ICI-induced BP. This number is higher than the estimated prevalence of autoimmune bullous diseases in the general population of Germany, which lies around 0.05%. We here describe our cohort of eight patients, who developed a bullous pemphigoid under or shortly after ICI treatment. Half of them had a severe subtype (as shown by BPDAI &amp;gt;57) and showed a median onset of ICI-BP after 10 months of ICI initiation. Six patients had a palmar and\/or plantar involvement, while oral involvement occurred in one case. All patients had linear epidermal IgG depositions in split skin in the indirect immunofluorescence. In four out of five biopsies available for direct immunofluorescence, linear IgG and C3 depositions were detected at the basement membrane, while one patient showed linear IgM staining. Moderate to high levels of FLBP180 autoantibodies were found in seven of eight cases. The disease can still be active after ICI discontinuation, while rituximab might be required for remission. Finally, four tumour samples were stained histochemically for collagen XVII (BP180), but no enhanced expression was found.<\/jats:p>","DOI":"10.3389\/fimmu.2022.953546","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T07:26:27Z","timestamp":1658561187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid\u2014A Retrospective, Monocentric Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Franziska","family":"Schauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rafei-Shamsabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Kiritsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-018-0676-z","article-title":"Melanoma and Immune Checkpoint Inhibitors","volume":"20","author":"Furue","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival With Ipilimumab in Patients With Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma Without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab Versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade With Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of Patients With Advanced Metastatic Melanoma: The Impact of MAP Kinase Pathway Inhibition and Immune Checkpoint Inhibition - Update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000356","article-title":"Immunotherapy to Treat Malignancy in Patients With Pre-Existing Autoimmunity","volume":"8","author":"Boland","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"552\u2013557","DOI":"10.1001\/jamadermatol.2022.0354","article-title":"Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors","volume":"158","author":"Said","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.032","article-title":"Methotrexate in the Treatment of Immune Checkpoint Blocker-Induced Bullous Pemphigoid","volume":"159","author":"Shi","year":"2021","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune Bullous Skin Disorders With Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12717","article-title":"Autoimmune Dermatologic Toxicities From Immune Checkpoint Blockade With Anti-PD-1 Antibody Therapy: A Report on Bullous Skin Eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous Pemphigoid, an Autoantibody-Mediated Disease, is a Novel Immune-Related Adverse Event in Patients Treated With Anti-Programmed Cell Death 1 Antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-012-0981-9","article-title":"Collagen XVII is Expressed in Malignant But Not in Benign Melanocytic Tumors and it can Mediate Antibody Induced Melanoma Apoptosis","volume":"138","author":"Krenacs","year":"2012","journal-title":"Histochem Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00403-021-02211-4","article-title":"Melanoma is Associated With an Increased Risk of Bullous Pemphigoid: A Large Population-Based Longitudinal Study","volume":"314","author":"Kridin","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14097_g","article-title":"S2k-Leitlinie Zur Therapie Des Pemphigus Vulgaris\/Foliaceus Und Des Bull\u00f6sen Pemphigoids: 2019 Update","volume":"18","author":"Schmidt","year":"2020","journal-title":"JDDG: J der Deutschen Dermatologischen Gesellschaft"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and Outcome Measures for Bullous Pemphigoid: Recommendations by an International Panel of Experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13717","article-title":"Management of Bullous Pemphigoid: The European Dermatology Forum Consensus in Collaboration With the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody Profile Differentiates Between Inflammatory and Noninflammatory Bullous Pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12488","article-title":"Late Presentation of Generalised Bullous Pemphigoid-Like Reaction in a Patient Treated With Pembrolizumab for Metastatic Melanoma","volume":"58","author":"Parakh","year":"2017","journal-title":"Australas J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103986","article-title":"IgG4 and IgE are the Major Immunoglobulins Targeting the NC16A Domain of BP180 in Bullous Pemphigoid: Serum Levels of These Immunoglobulins Reflect Disease Activity","volume":"42","author":"D\u00f6pp","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.017","article-title":"Immunoglobulin M Pemphigoid","volume":"85","author":"Boch","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16260","article-title":"Super-Resolution Imaging Detects BP180 Autoantigen in Immunoglobulin M Pemphigoid","volume":"49","author":"Hirano","year":"2022","journal-title":"J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.01.013","article-title":"In Vivo Analysis of IgE Autoantibodies in Bullous Pemphigoid: A Study of 100 Cases","volume":"78","author":"Moriuchi","year":"2015","journal-title":"J Dermatol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57040398","article-title":"Dyshidrosiform Bullous Pemphigoid","volume":"57","author":"Cohen","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4052","article-title":"Dyshidrosiform Pemphigoid Due to Nivolumab Therapy","volume":"31","author":"Hayashi","year":"2021","journal-title":"Eur J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid Diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study","volume":"131","author":"Di Zenzo","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01224","article-title":"Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180","volume":"10","author":"Mai","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/002215540305100707","article-title":"Alterations of Collagen XVII Expression During Transformation of Oral Epithelium to Dysplasia and Carcinoma","volume":"51","author":"Parikka","year":"2003","journal-title":"J Histochem Cytochem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14867","article-title":"BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma","volume":"41","author":"Meng","year":"2021","journal-title":"Anticancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051296","article-title":"Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated With Treatment Outcomes in Melanoma? A Population-Based Study","volume":"14","author":"Nikita","year":"2022","journal-title":"Cancers"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz449.001","article-title":"Association of Systemic Corticosteroids With Overall Survival in Patients Receiving Cancer Immunotherapy for Advanced Melanoma, non-Small Cell Lung Cancer or Urothelial Cancer in Routine Clinical Practice","volume":"30","author":"Drakaki","year":"2019","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2019.3751","article-title":"Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"146","author":"Tam","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2145-9","article-title":"Rituximab as a Therapeutic Option for Patients With Advanced Melanoma","volume":"67","author":"Winkler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103483","article-title":"Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"IJMS"},{"key":"B43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the Treatment of Nivolumab-Induced Bullous Pemphigoid: A Case Report and Review of the Literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02377-x","article-title":"Successful Combination Therapy of Systemic Checkpoint Inhibitors and Intralesional Interleukin-2 in Patients With Metastatic Melanoma With Primary Therapeutic Resistance to Checkpoint Inhibitors Alone","volume":"68","author":"Rafei-Shamsabadi","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1158901","article-title":"Predictive Immune Markers in Advanced Melanoma Patients Treated With Ipilimumab","volume":"5","author":"Umansky","year":"2016","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16679","article-title":"Peripheral Eosinophilia in Bullous Pemphigoid: Prevalence and Influence on the Clinical Manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00201","article-title":"The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.547","article-title":"Malignancies in Pemphigus and Pemphigoid Diseases","volume":"135","author":"Schulze","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13200","article-title":"Cutaneous Adverse Events in Patients Treated With BRAF Inhibitor-Based Therapies for Metastatic Melanoma for Longer Than 52 Weeks","volume":"172","author":"Anforth","year":"2015","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in Patients With Metastatic Melanoma: Cutaneous Manifestations of Dabrafenib (GSK2118436)","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13023-015-0278-x","article-title":"Prevalence of Pemphigus and Pemphigoid Autoantibodies in the General Population","volume":"10","author":"Pr\u00fc\u00dfmann","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148674","article-title":"Detection of Autoreactive CD4+ T Cells by MHC Class II Multimers in HLA-Linked Human Autoimmune Diseases","volume":"131","author":"Wieber","year":"2021","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T07:26:30Z","timestamp":1658561190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2022.953546"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.953546","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"article-number":"953546"}}